InvestorsHub Logo
Followers 12
Posts 762
Boards Moderated 0
Alias Born 02/06/2021

Re: None

Wednesday, 06/16/2021 6:17:30 PM

Wednesday, June 16, 2021 6:17:30 PM

Post# of 349
Comment off yahoo finance:

The 12-month combined phase 2 and 3 trials (completed in Jan 2019) showed 80% reduction in NPC in the patients group. The 24-months extension trials (completed in Jan 2020) were even better, it showed 90% reduction in NPC. Drug was very well-telorated with very high safety results. FDA loves it.